C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesteremia
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca
Summary
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in
statin-naive patients and in patients with previously unsuccessful statin therapy. This study
was designed to investigate the dynamic of the lipid parameters and therapy tolerability
during 8-10 weeks treatment with CRESTOR
Clinical Details
Official title: C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
Study design: Other, Prospective
Primary outcome: LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
Secondary outcome: Tolerability of CRESTOR-therapy
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with hypercholesteremia who was never treated with statins before
- Patient with hypercholesteremia who was treated with a statin (other then
rosuvastatin) but because of its adverse effects/insufficient action was switched to
therapy with CRESTOR
Exclusion Criteria:
- None
Locations and Contacts
Additional Information
Starting date: February 2007
Ending date: August 2007
Last updated: June 2, 2008
|
